Research progress of oral anticoagulants in patients with liver diseases
10.3760/cma.j.issn.1007-3418.2018.11.015
- VernacularTitle: 口服抗凝药在肝病患者中应用的研究进展
- Author:
Shipeng ZHAN
1
;
Min TANG
;
Fang LIU
;
Peiyuan XIA
Author Information
1. Department of Pharmacy, the First Affiliated Hospital of Army Medical University, Chongqing 400038, China
- Publication Type:Review
- Keywords:
Liver disease;
Thrombosis;
Warfarin;
Non-vitamin K antagonist oral anticoagulants
- From:
Chinese Journal of Hepatology
2018;26(11):873-876
- CountryChina
- Language:Chinese
-
Abstract:
Patients with liver disease are at an increased risk of both embolism and bleeding. The optimal anticoagulation strategy remains unclear when associated with venous thromboembolic disease. Moreover, currently approved oral anticoagulant drugs undergo metabolism and elimination in the liver with varying degrees of hepatic dysfunction. Thus, impaired liver function may lead to increased risk of bleeding, making anticoagulant therapy more intricate. This article summarizes the risk of bleeding and thrombosis in patients with liver disease, and the clinical research progress of oral anticoagulants in patients with liver disease to facilitate evidence for choosing oral anticoagulants therapy when required.
